Publication: Desarrollo galénico de nuevas formulaciones de nistatina para uso en candidiasis oral
Loading...
Files
Official URL
Full text at PDC
Publication Date
2019-11-21
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
La infección de la mucosa oral por Candida albicans es una patología creciente a nivel mundial debido al gran número de pacientes inmunodeprimidos, hospitalizados de larga duración o que requieren dispositivos de uso clínico. Aunque en pacientes sanos, estas infecciones suelen ser autolimitantes, en pacientes con el sistema inmune comprometido pueden llegar a constituir un grave problema de salud debido a la capacidad de desarrollar resistencias, la dificultad en el manejo de la infección y la formación de biopelículas por parte del hongo, que impiden la penetración del compuesto antifúngico. De hecho, estas biopelículas son un factor de mal pronóstico en enfermos intubados o cateterizados. Nistatina, un antifúngico polieno muy conocido, con un adecuado perfil de actividad antifúngica y asequible económicamente ha demostrado tener capacidad inhibitoria del desarrollo de estas biopelículas y puede constituir una excelente elección como tratamiento de la candidiasis oral...
The infection of the oral mucosa by Candida albicans is a growing pathology worldwide due to the large number of immunosuppressed patients, long-term hospitalizations or patients requiring clinical devices. Although in healthy patients, these infections are usually self-limiting, in patients with compromised immune system can become a serious problem because of the ability to develop resistances, the difficulty in handling the infection and the formation of biofilms by the fungus, which prevent the penetration of the antifungal compound. In fact, these biofilms are a factor of poor prognosis in intubated or catheterized patients. Nystatin, a well-known polyene antifungal, with an adequate profile of antifungal activity and economically available, has an inhibitory effect for the development of these biofilms and can be an excellent choice as a treatment for oral candidiasis...
The infection of the oral mucosa by Candida albicans is a growing pathology worldwide due to the large number of immunosuppressed patients, long-term hospitalizations or patients requiring clinical devices. Although in healthy patients, these infections are usually self-limiting, in patients with compromised immune system can become a serious problem because of the ability to develop resistances, the difficulty in handling the infection and the formation of biofilms by the fungus, which prevent the penetration of the antifungal compound. In fact, these biofilms are a factor of poor prognosis in intubated or catheterized patients. Nystatin, a well-known polyene antifungal, with an adequate profile of antifungal activity and economically available, has an inhibitory effect for the development of these biofilms and can be an excellent choice as a treatment for oral candidiasis...
Description
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Farmacia, Departamento de Farmacia Galénica y Tecnología Alimentaria, leída el 03-10-2019